

RESEARCH

Open Access

Interleukin-27 is a novel candidate diagnostic biomarker for bacterial infection in critically ill children

Hector R Wong^{1,2*}, Natalie Z Cvijanovich³, Mark Hall⁴, Geoffrey L Allen⁵, Neal J Thomas⁶, Robert J Freishtat⁷, Nick Anas⁸, Keith Meyer⁹, Paul A Checchia¹⁰, Richard Lin¹¹, Michael T Bigham¹², Anita Sen¹³, Jeffrey Nowak¹⁴, Michael Quasney¹⁵, Jared W Henricksen¹⁶, Arun Chopra¹⁷, Sharon Banschbach¹, Eileen Beckman¹, Kelli Harmon¹, Patrick Lahni¹ and Thomas P Shanley¹⁸

Abstract

Introduction: Differentiating between sterile inflammation and bacterial infection in critically ill patients with fever and other signs of the systemic inflammatory response syndrome (SIRS) remains a clinical challenge. The objective of our study was to mine an existing genome-wide expression database for the discovery of candidate diagnostic biomarkers to predict the presence of bacterial infection in critically ill children.

Methods: Genome-wide expression data were compared between patients with SIRS having negative bacterial cultures ($n = 21$) and patients with sepsis having positive bacterial cultures ($n = 60$). Differentially expressed genes were subjected to a leave-one-out cross-validation (LOOCV) procedure to predict SIRS or sepsis classes. Serum concentrations of interleukin-27 (IL-27) and procalcitonin (PCT) were compared between 101 patients with SIRS and 130 patients with sepsis. All data represent the first 24 hours of meeting criteria for either SIRS or sepsis.

Results: Two hundred twenty one gene probes were differentially regulated between patients with SIRS and patients with sepsis. The LOOCV procedure correctly predicted 86% of the SIRS and sepsis classes, and Epstein-Barr virus-induced gene 3 (*EBI3*) had the highest predictive strength. Computer-assisted image analyses of gene-expression mosaics were able to predict infection with a specificity of 90% and a positive predictive value of 94%. Because *EBI3* is a subunit of the heterodimeric cytokine, IL-27, we tested the ability of serum IL-27 protein concentrations to predict infection. At a cut-point value of ≥ 5 ng/ml, serum IL-27 protein concentrations predicted infection with a specificity and a positive predictive value of $>90\%$, and the overall performance of IL-27 was generally better than that of PCT. A decision tree combining IL-27 and PCT improved overall predictive capacity compared with that of either biomarker alone.

Conclusions: Genome-wide expression analysis has provided the foundation for the identification of IL-27 as a novel candidate diagnostic biomarker for predicting bacterial infection in critically ill children. Additional studies will be required to test further the diagnostic performance of IL-27. The microarray data reported in this article have been deposited in the Gene Expression Omnibus under accession number GSE4607.

* Correspondence: hector.wong@cchmc.org

¹Division of Critical Care Medicine, Cincinnati Children's Hospital Medical Center and Cincinnati Children's Research Foundation, 3333 Burnet Ave, Cincinnati, OH 45223, USA

Full list of author information is available at the end of the article

Introduction

Differentiating between sterile inflammation and bacterial infection in critically ill patients with fever and other signs of the systemic inflammatory response syndrome (SIRS) remains a clinical challenge [1-3]. Standard microbiology culture techniques remain the gold standard, but they can lack sensitivity, and often, a substantial delay occurs between obtaining cultures and generating clinically useful data. Consequently, a great deal of interest exists in developing biomarkers to differentiate sepsis from noninfectious causes of SIRS before microbiology data become available [4].

We generated a large genome-wide expression database (transcriptomics) of critically ill children with SIRS, sepsis, and septic shock by way of microarray technology [5-18]. In the current study, we mined these data to discover gene signatures having the potential to differentiate sepsis from noninfectious causes of SIRS. Herein we report that interleukin-27 (IL-27) may represent a novel diagnostic biomarker for predicting bacterial infection in critically ill patients.

Materials and methods

Patients and data collection

The study protocol was approved by the Institutional Review Boards of each participating institution ($n = 17$) and was previously described in detail [14,18]. In brief, children 10 years of age or younger admitted to the pediatric intensive care unit (PICU) and meeting pediatric-specific criteria for SIRS, sepsis, or septic shock were eligible for enrollment [19]. After informed consent from parents or legal guardians, we obtained blood samples within 24 hours of initial presentation to the PICU with SIRS, sepsis, or septic shock. Clinical and laboratory data were collected daily while patients were in the PICU, and stored by using a Web-based database. Mortality was tracked for 28 days after enrollment, and organ-failure data were based on pediatric-specific criteria [19]. Control samples were obtained from healthy children in the ambulatory departments of participating institutions by using previously published inclusion and exclusion criteria [18].

All patients with microarray data in the current study were previously reported in studies addressing hypotheses entirely different from that of the current report [7,9-16,18,20]. For the current study, all patients in the sepsis and septic-shock cohorts had clinical microbiology laboratory confirmation of a bacterial pathogen from blood cultures or other normally sterile body fluids, whereas all patients in the SIRS cohort had negative bacterial cultures.

RNA extraction, microarray hybridization, and microarray analysis

Total RNA was isolated from whole-blood samples by using the PaxGene Blood RNA System (PreAnalytiX;

Qiagen/Becton Dickinson, Valencia, CA, USA) according to the manufacturer's specifications. Microarray hybridization was performed by the Affymetrix Gene Chip Core facility at Cincinnati Children's Hospital Research Foundation, as previously described, by using the Human Genome U133 Plus 2.0 GeneChip (Affymetrix, Santa Clara, CA, USA) [18].

Analyses were performed by using one patient sample per chip. Image files were captured by using an Affymetrix GeneChip Scanner 3000. Raw data files were subsequently preprocessed by using Robust Multiple-array Average (RMA) normalization with GeneSpring GX 7.3 software (Agilent Technologies, Palo Alto, CA, USA) [21]. All chips were then normalized to the respective median values of normal, age-matched controls, as previously described [18]. Differences in mRNA abundance between patient samples were determined by using GeneSpring GX 7.3. All statistical analyses used corrections for multiple comparisons. The specific statistical and filtering approaches for identifying differentially regulated genes are provided in the Results section because of their relevance to data interpretation. All microarray data have been deposited in the Gene Expression Omnibus [22] under accession number GSE4607.

Generation of gene-expression mosaics

Gene-expression mosaics were generated by using the Gene Expression Dynamics Inspector (GEDI) platform. GEDI is a publicly available gene-expression analysis program developed by the Ingber Laboratory at Harvard University [23,24]. The signature graphic outputs of GEDI are gene-expression mosaics that give microarray data a "face" that is intuitively recognizable by human pattern recognition [10,11]. The underlying algorithm for creating the mosaics is a self-organizing map (SOM).

Computer-assisted image analysis

Individual patient mosaics were compared with SIRS and sepsis reference mosaics by using a publicly available image-analysis platform (ImageJ), as previously described [10]. In brief, the absolute difference in RGB pixel-to-pixel intensity was calculated for each individual patient mosaic relative to the SIRS and sepsis reference mosaics. Final classification was based on the "least difference" between the individual patient mosaic and the two reference mosaics.

Measurement of IL-27 and procalcitonin serum protein concentrations

Serum IL-27 (EMD Millipore Corporation, Billerica, MA, USA) and procalcitonin (Bio-Rad, Hercules, CA, USA) protein concentrations were measured by using a magnetic bead multiplex platform and a Luminex 100/200 System (Luminex Corporation, Austin, TX, USA), according to the manufacturers' specifications.

Statistical analysis

Initially, data are described by using medians, interquartile ranges (IQRs), and percentages. Comparisons between study cohorts used the Mann-Whitney *U* test, χ^2 , or Fisher Exact tests, as appropriate. Descriptive statistics and comparisons used SigmaStat Software (Systat Software, Inc., San Jose, CA, USA). Classification and regression tree (CART) analysis was conducted by using the Salford Predictive Modeler v6.6 (Salford Systems, San Diego, CA, USA) [25]. Biomarker test characteristics are reported by using diagnostic test statistics with 95% confidence intervals computed by using the score method, as implemented by VassarStats Website for Statistical Computation [26].

Results

Initial identification of candidate sepsis diagnostic genes

Candidate sepsis diagnostic genes were identified by analyzing existing patients in our genome-wide expression database of critically ill children meeting criteria for either SIRS with negative bacterial cultures ($n = 21$) or sepsis with positive bacterial cultures ($n = 60$). All gene-expression data reflect the first 24 hours of meeting clinical criteria for SIRS or sepsis. Fifty-three of the patients with sepsis also met criteria for septic shock. The basic clinical and demographic characteristics of the SIRS and sepsis cohorts are shown in Table 1. Patients in the sepsis cohort were younger and had a higher PRISM score compared with patients in the SIRS cohort.

The initial step for identifying candidate sepsis diagnostic genes consisted of an expression filter. Starting with all gene probes on the array (>80,000), we selected gene probes having ≥ 2 -fold expression between the median values of patients with sepsis and patients with SIRS, respectively. This expression filter yielded 228 gene probes. We next subjected the 228 gene probes to a statistical test (ANOVA with a Benjamini-Hochberg false-discovery rate of 5%) by using the sepsis and SIRS cohorts as the comparison groups. This statistical test yielded 221 gene probes differentially regulated between patients with sepsis and patients with SIRS.

We then performed a leave-one-out cross-validation (LOOCV) procedure to determine whether the overall expression patterns of the 221 differentially regulated

gene probes could identify SIRS and sepsis classes. The LOOCV procedure correctly predicted 86% of the SIRS or sepsis classes. The top 100 class-predictor genes (based on predictive strength) are provided in Additional file 1. Epstein-Barr virus-induced gene 3 (*EBI3*) had the highest predictive strength.

Gene-expression mosaics of the top 100 class-predictor genes

The expression values of the top 100 class-predictor genes were uploaded to the GEDI platform, and reference gene-expression mosaics were generated for patients with SIRS and patients with sepsis, respectively (Figure 1A). The reference mosaics represent the average expression patterns for all patients in each class and demonstrate distinct expression patterns for the patients with sepsis compared with the patients with SIRS. Examples of individual patient mosaics are provided in Figure 1B.

We next performed computer-assisted image analysis to determine whether the expression mosaics could correctly identify SIRS and sepsis classes. The image-analysis algorithm compared individual patient mosaics with the two reference mosaics and assigned the individual patients to either SIRS or sepsis classes, based on similarity of expression [10]. The test characteristics of this analysis are provided in Table 2. The expression mosaics were able to identify patients with infection (sepsis) with a high degree of specificity (90%) and a high positive predictive value (94%). Thus, the top 100 class-predictor genes represent a potential working list of candidate diagnostic biomarkers for the presence of bacterial infection in critically ill patients.

IL-27 as a diagnostic biomarker for bacterial infection in critically ill patients


As previously noted, *EBI3* had the highest predictive strength for bacterial infection in this cohort of critically ill children. *EBI3* is a subunit of the heterodimeric cytokine, IL-27, which is produced by antigen-presenting cells and plays a role in regulating T-cell function [27]. Because IL-27 protein concentrations can be readily measured in the serum compartment, we tested IL-27 serum protein concentrations as a diagnostic biomarker for bacterial infection in critically ill children.

We measured IL-27 serum protein concentrations in 61 healthy control children and in a cohort of 231 critically ill children. One hundred and one critically ill children met criteria for SIRS and had negative bacterial cultures; 38 met criteria for sepsis and had positive bacterial cultures; and 92 met criteria for septic shock and had positive bacterial cultures. All serum samples represent the first 24 hours of meeting clinical criteria for SIRS, sepsis, or septic shock. The basic clinical and demographic characteristics of this cohort, and the

Table 1 Clinical characteristics of the gene-expression cohort

	SIRS ($n = 21$)	Sepsis ($n = 60$)
Median age in years	3.3 (2.0 to 8.3)	1.9 (0.6 to 5.1) ^a
Males (%)	52	67
Median PRISM score	10 (4 to 14)	14 (10 to 21) ^a
Mortality (%)	5	22

^a $P < 0.05$ versus procalcitonin (PCT); PRISM, pediatric risk of mortality; SIRS, systemic inflammatory response syndrome.



respective median IL-27 concentrations, are shown in Table 3. Patients with SIRS had significantly lower IL-27 serum protein concentrations compared with patients with sepsis and patients with septic shock. Controls had significantly lower IL-27 serum protein concentrations compared with all classes of critically ill patients.

To determine the ability of serum IL-27 concentrations to predict bacterial infection in critically ill patients, we grouped the patients with sepsis and septic shock as positive cases for infection, and compared them with the SIRS patients as negative cases for infection. The area under the curve (AUC) for the receiver operating characteristic (ROC) curve was 0.811 (0.755 to 0.868). The IL-27 test characteristics for predicting infection in critically ill patients are provided in Table 4. At a cut point of ≥ 5.0 ng/ml, serum IL-27 had a

specificity and positive predictive value of $>90\%$ for bacterial infection in this cohort of critically ill patients. Collectively, these data indicate that serum IL-27 can potentially serve as an effective “rule-in” test for bacterial infection in critically ill patients.

Comparison with procalcitonin

Because procalcitonin (PCT) is currently being used clinically as a biomarker for bacterial infection in critically ill patients, we also measured serum PCT concentrations in the same cohort of patients. As shown in Table 3, patients with septic shock had significantly higher PCT concentrations compared with patients with SIRS or sepsis, but the PCT concentrations were not significantly different between patients with SIRS and patients with sepsis. PCT concentrations yielded an AUC of 0.744 (0.680 to 0.808; $P = 0.049$ versus the AUC for IL-27). The PCT test characteristics for predicting infection in critically patients are provided in Table 5. These data demonstrate that IL-27 generally performs better than PCT for predicting infection in this cohort of critically ill patients.

Combining IL-27 and PCT

We next conducted CART analysis to determine whether a combination of serum IL-27 and PCT concentrations

Table 2 Test characteristics of gene-expression mosaics for identifying sepsis versus systemic inflammatory response syndrome (SIRS)

	%	95% Confidence interval
Sensitivity	53	39-66
Specificity	90	68-98
Positive predictive value	94	78-99
Negative predictive value	40	27-56

Table 3 Clinical characteristics of the interleukin-27 cohort

	Controls (n = 61)	SIRS (n = 101)	Sepsis (n = 38)	Septic shock (n = 92)
Median age in years	4.3 (1.2-6.5)	3.8 (1.2-6.4)	1.3 (0.4-5.3) ^a	2.4 (0.9-5.8)
Males (%)	57	58	58	64
Median PRISM score	-	7 (2-11)	7 (5-13)	14 (8-21) ^b
Mortality (%)	-	0	5	14 ^c
Median IL-27 (ng/ml)	1.0 (0.7-1.6) ^d	2.5 (1.6-3.7) ^e	6.1 (3.6-9.5)	5.9 (3.2-10.9)
Median PCT (ng/ml)	-	1.3 (0.1-2.4)	1.8 (0.1-4.9)	6.1 (2.7-20.5) ^b

PRISM, pediatric risk of mortality; SIRS, systemic inflammatory response syndrome. ^a*P* < 0.05 versus Controls. ^b*P* < 0.05 versus SIRS and sepsis. ^c*P* < 0.05 versus SIRS. ^d*P* < 0.05 versus SIRS, sepsis, and septic shock. ^e*P* < 0.05 versus sepsis and septic shock.

could further improve the ability to predict infection in critically ill patients [25]. The optimal decision tree generated by CART analysis is shown in Figure 2. The decision tree consists of two decision rules and three terminal nodes. Subjects in terminal node 1 had a 19.4% risk of infection. Subjects in terminal nodes 2 and 3 had a 65.3% and a 90.9% risk of infection, respectively. To calculate the global test characteristics of the decision tree, we classified all subjects in terminal node 1 as “not infected” and all subjects in terminal nodes 2 and 3 as “infected.” This approach yielded an AUC of 0.846, a sensitivity of 86% (79% to 91%), a specificity of 75% (65% to 83%); a positive predictive value of 82% (74% to 88%), and a negative predictive value of 81% (71% to 88%). Collectively, these data demonstrate that a combination of IL-27 and PCT improves the overall ability to predict infection in this cohort of critically ill patients, compared with either biomarker alone.

Discussion

We previously reported differential patterns of gene expression across the SIRS, sepsis, and septic-shock clinical spectrum [14]. In that previous study, however, the classifications of “sepsis” and “septic shock” were based on either laboratory confirmation of a pathogen, or high clinical suspicion of infection, according to published, pediatric specific criteria [19]. The current analysis is specifically targeted toward identification of patients with signs of inflammation and laboratory confirmation of a bacterial pathogen. Accordingly, all of the patients in the current study who met criteria for sepsis and septic shock also had laboratory confirmation of a bacterial pathogen.

Based on this analytic approach, we leveraged the discovery potential of microarray-based transcriptomics and generated a list of genes differentially regulated between critically ill patients with SIRS (that is, patients with sterile systemic inflammation) and critically ill patients with sepsis (that is, patients with systemic inflammation secondary to a documented bacterial pathogen). This gene list represents a potential working list of candidate diagnostic biomarkers for bacterial infection in critically ill patients. The global expression patterns of the top 100 class-predictor genes were able to predict SIRS and sepsis classes with high specificity and a high positive predictive value.

Generating gene-expression data and gene-expression mosaics for 100 genes may not yet be clinically feasible within the time-sensitive constraints of the intensive care unit. Accordingly, we investigated the ability of serum IL-27 protein concentrations to predict bacterial infection in critically ill patients. The rationale for investigating IL-27 is based on the observation that *EBI3* had the highest predictive strength for bacterial infection of all genes differentially regulated between patients with SIRS and patients with sepsis. IL-27 is a heterodimeric cytokine belonging the IL-6 and IL-12 family of cytokines and is composed of the IL-27-p28 and *EBI3* subunits, which are produced by antigen-presenting cells on exposure to microbial products and inflammatory stimuli [27]. IL-27 is a regulator T-cells, having both pro- and antiinflammatory effects [28,29], and is rapidly induced in a murine model of septic peritonitis [30]. Furthermore, genetic ablation of *EBI3* or neutralization of IL-27 via a soluble IL-27 receptor fusion protein is protective in a murine model of septic peritonitis [30].

Table 4 Interleukin 27 (IL-27) test characteristics for predicting bacterial infection

Cut point ≥ (ng/ml)	Sensitivity	Specificity	Positive predictive value	Negative predictive value
2.0	92% (86-96)	35% (26-45)	65% (58-72)	78% (62-88)
3.0	79% (71-86)	60% (50-70)	72% (64-79)	69% (58-78)
4.0	69% (61-77)	82% (73-89)	83% (75-90)	67% (58-75)
5.0	61% (52-69)	92% (84-96)	91% (82-96)	64% (56-72)
6.0	51% (42-60)	96% (89-99)	94% (85-98)	60% (52-68)

Table 5 Procalcitonin (PCT) test characteristics for predicting bacterial infection

Cut point \geq (ng/ml)	Sensitivity	Specificity	Positive predictive value	Negative predictive value
0.5	88% (81-93)	30% (21-40)	62% (55-69)	67% (51-80)
1.0	85% (77-90)	37% (28-47)	64% (56-71)	65% (51-77)
2.0	70% (61-78)	62% (52-71)	70% (62-78)	61% (51-71)
3.0	63% (54-71)	82% (73-89)	82% (73-89)	63% (54-71)
4.0	56% (47-65)	87% (78-93)	85% (75-91)	60% (52-68)

Thus, it is biologically plausible that IL-27 can serve as a biomarker of bacterial infection in critically ill patients.


Serum IL-27 protein levels ≥ 5 ng/ml, obtained within the first 24 hours of meeting clinical criteria for SIRS/sepsis, had a high specificity and a high positive predictive value for predicting bacterial infection in our cohort of more than 200 critically ill patients with SIRS or sepsis. Thus, serum IL-27 has the potential to serve as an effective “rule-in” test, given that concentrations ≥ 5 ng/ml had a $>90\%$ specificity and positive predictive value for bacterial infection in this cohort of critically ill patients. Conversely, serum IL-27 protein concentrations <5 ng/ml do not necessarily rule out bacterial infection, given that the negative predictive value for a concentration ≥ 2 ng/ml was 78%. Finally, it does not appear that increased IL-27 protein concentration in critically ill children with bacterial infection reflects increased illness severity, because the median IL-27 concentrations were similar between patients with sepsis and patients with septic shock.

PCT has emerged as a widely used diagnostic biomarker for bacterial infection in clinical practice. However,

the performance of PCT varies depending on the patient population in which it is applied, and a meta-analysis by Tang *et al.* [1] concluded that PCT does not reliably differentiate sepsis from noninfectious causes of SIRS in critically ill adults. In our study population, PCT concentrations were not significantly different between patients with SIRS and patients with sepsis; and IL-27 generally performed better than PCT as a diagnostic biomarker based on the AUC and the test characteristics calculated for various cut points.

Given the biologic complexity and heterogeneity of critical illness, it is unlikely that any one biomarker will consistently predict the presence of bacterial infection. Accordingly, a strategy that combines diagnostic biomarkers may perform better than any single biomarker [2,31]. With a combination of IL-27 and PCT, we were able to demonstrate an improved overall ability to both “rule in” and “rule out” bacterial infection in this cohort of critically ill patients.

Several strengths of our study design are worthy of discussion. First, we selected IL-27 as a candidate diagnostic marker in an objective manner, by using the



discovery potential of transcriptomics. Second, our study cohort was relatively large, and all patients in the sepsis cohort had formal microbiologic confirmation of bacterial infection. Third, the study cohort represents patients from 17 different institutions. Finally, the serum IL-27 data reflect the first 24 hours of meeting criteria for either SIRS or sepsis, which is a clinically relevant time point for the prediction of bacterial infection in critically ill patients.

Our study also has a number of limitations worthy of discussion. First, although *EBI3* mRNA levels had the highest predictive strength, we did not directly measure serum *EBI3* protein concentrations, because it was technically more pragmatic to measure serum IL-27 concentrations. Second, *EBI3* is also a subunit for IL-35, but we were unable to measure serum IL-35 concentrations for technical reasons. Third, we cannot exclude the possibility that some of the patients in the SIRS cohort had bacterial infections that were undetectable by conventional microbiologic cultures. Fourth, our data are limited to critically ill children and may not be generalizable to other clinical settings. Finally, we have no data regarding the temporal production of IL-27 during the course of bacterial infection. These limitations provide further research opportunities for future studies.

Conclusions

Genome-wide expression analysis has provided the foundation for the identification of IL-27 as a novel candidate diagnostic biomarker for predicting bacterial infection in critically ill patients. We also demonstrated that a combination of IL-27 and PCT improves the overall ability to predict infection, compared with that of either biomarker alone. Additional studies will be required to test further the diagnostic capabilities of IL-27.

Key messages

- By using microarray analysis, we identified 221 gene probes that are differentially regulated between patients with SIRS and patients with sepsis.
- The expression patterns of these differentially regulated gene probes can distinguish patients with SIRS and patients with sepsis with a high specificity and positive predictive value.
- Epstein-Barr virus-induced gene 3 (*EBI3*), a subunit of IL27, has the highest predictive strength among the 221 differentially regulated gene probes.
- Serum IL27 protein concentrations had a high specificity and positive predictive value for predicting bacterial infection in a cohort of critically ill children.
- The performance of IL27 was generally superior to that of procalcitonin in this cohort.

Additional material

Additional file 1: Top 100 class-predictor genes. A list of the top 100 predictor genes for bacterial infection

Abbreviations

AUC: area under the curve; CART: classification and regression tree; *EBI3*: Epstein-Barr virus-induced gene 3; GEDI: Gene Expression Dynamics Inspector; IL-27: interleukin-27; IQR: interquartile range; LOOCV: leave-one-out cross validation; PCT: procalcitonin; PICU: pediatric intensive care unit; PRISM: pediatric risk of mortality; ROC: receiver-operating characteristic; SIRS: systemic inflammatory response syndrome.

Acknowledgements

Supported by National Institutes of Health Grants RC1HL100474 and RO1GM064619 to HRW. Supported, in part, by the National Center for Advancing Translational Sciences, National Institutes of Health Grant UL1TR000040.

The authors thank the following research coordinators for their effort and dedication in enrolling study participants: Tasha Capozzi, Mary Ann De Liberto, Mercedes Galera-Perez, Kristin Greathouse, Lauren Hoadley, Katherine Luther, Stephanie Osborne, Amber Hughes-Schalk, Tonia Polanski, Julie Simon, Debra Spear, Lisa Steele, Naresh B. Talathoti, Tiffany Vertican, Monica Weber, Andrew A. Wiles, Trisha Williams, and Erin Zielinski.

Author details

¹Division of Critical Care Medicine, Cincinnati Children's Hospital Medical Center and Cincinnati Children's Research Foundation, 3333 Burnet Ave, Cincinnati, OH 45223, USA. ²Department of Pediatrics, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267, USA. ³Division of Critical Care Medicine, Children's Hospital and Research Center Oakland, 744 52nd Street, Oakland, CA 94609, USA. ⁴Division of Critical Care Medicine, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43205, USA. ⁵Division of Critical Care Medicine, Children's Mercy Hospital, 2401 Gilham Road, Kansas City, MO 64108, USA. ⁶Division of Critical Care Medicine, Penn State Hershey Children's Hospital, 500 University Drive, Hershey, PA 17033, USA. ⁷Division of Emergency Medicine, Children's National Medical Center, 111 Michigan Avenue, Washington, DC 20010, USA. ⁸Division of Critical Care Medicine, Children's Hospital of Orange County, 455 South Main Street, Orange, CA 92868, USA. ⁹Division of Critical Care Medicine, 3100 SW 62nd Avenue, Miami Children's Hospital, Miami, FL 33155, USA. ¹⁰Division of Critical Care Medicine, 6621 Fannin Street, Texas Children's Hospital, Houston, TX 77030, USA. ¹¹Division of Critical Care Medicine, The Children's Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Philadelphia, PA 19104, USA. ¹²Division of Critical Care Medicine, Akron Children's Hospital, One Perkins Square, Akron, OH 44308, USA. ¹³Division of Critical Care Medicine, Morgan Stanley Children's Hospital, Columbia University Medical Center, 3959 Broadway, New York, NY 10032, USA. ¹⁴Division of Critical Care Medicine, Children's Hospital and Clinics of Minnesota, 2525 Chicago Avenue South, Minneapolis, MN 55404, USA. ¹⁵Division of Critical Care Medicine, Children's Hospital of Wisconsin, 9000 W Wisconsin Avenue, Milwaukee, WI 53201, USA. ¹⁶Division of Critical Care Medicine, Primary Children's Medical Center, 100 Mario Capecchi Drive, Salt Lake City, UT 84113, USA. ¹⁷Division of Critical Care Medicine, St Christopher's Hospital for Children, 3601 A Street, Philadelphia, PA 19134, USA. ¹⁸Division of Critical Care Medicine, CS Mott Children's Hospital at the University of Michigan, Ann Arbor, MI 48103, USA.

Authors' contributions

HRW conceived and developed the study, obtained funding for the study, conducted the analyses, and wrote the manuscript. NZC, MH, GLA, NJT, RJF, NA, KM, PAC, RL, MTB, AS, JN, MQ, JH, AC, and TPS enrolled patients, provided biologic samples and clinical data for the database, and edited the manuscript. SB and EB coordinated patient enrolment among the various study sites, maintained the clinical database, and edited the manuscript. KH coordinated biologic-sample procurement and submission among the various study sites, maintained the biologic-specimen repository, and edited

the manuscript. PL conducted all biomarker measurements and edited the manuscript. All authors read and approved the manuscript for publication.

Competing interests

HRW and the Cincinnati Children's Hospital Research Foundation have submitted a provisional patent application for the use of IL-27 as a diagnostic biomarker for sepsis.

The remaining authors have no competing interests to report.

Received: 17 July 2012 Revised: 9 October 2012

Accepted: 26 October 2012 Published: 29 October 2012

References

1. Tang BM, Eslick GD, Craig JC, McLean AS: **Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis.** *Lancet Infect Dis* 2007, **7**:210-217.
2. Sutherland A, Thomas M, Brandon RA, Brandon RB, Lipman J, Tang B, McLean A, Pascoe R, Price G, Nguyen T, Stone G, Venter D: **Development and validation of a novel molecular biomarker diagnostic test for the early detection of sepsis.** *Crit Care* 2011, **15**:R149.
3. Tang BM, McLean AS, Dawes IW, Huang SJ, Lin RC: **The use of gene-expression profiling to identify candidate genes in human sepsis.** *Am J Resp Crit Care Med* 2007, **176**:676-684.
4. Marshall JC, Reinhart K: **Biomarkers of sepsis.** *Crit Care Med* 2009, **37**:2290-2298.
5. Wong HR: **Genetics and genomics in pediatric septic shock.** *Crit Care Med* 2012, **40**:1618-1626.
6. Wong HR: **Clinical review: sepsis and septic shock: the potential of gene arrays.** *Crit Care* 2012, **16**:204.
7. Basu RK, Standage SW, Cvijanovich NZ, Allen GL, Thomas NJ, Freishtat RJ, Anas N, Meyer K, Checchia PA, Lin R, Shanley TP, Bigham MT, Wheeler DS, Devarajan P, Goldstein SL, Wong HR: **Identification of candidate serum biomarkers for severe septic shock-associated kidney injury via microarray.** *Crit Care* 2011, **15**:R273.
8. Solan PD, Dunsmore KE, Denenberg AG, Odoms K, Zingarelli B, Wong HR: **A novel role for matrix metalloproteinase-8 in sepsis.** *Crit Care Med* 2012, **40**:379-387.
9. Wynn JL, Cvijanovich NZ, Allen GL, Thomas NJ, Freishtat RJ, Anas N, Meyer K, Checchia PA, Lin R, Shanley TP, Bigham MT, Bansbach S, Beckman E, Wong HR: **The influence of developmental age on the early transcriptomic response of children with septic shock.** *Mol Med* 2011, **17**:1146-1156.
10. Wong HR, Cvijanovich NZ, Allen GL, Thomas NJ, Freishtat RJ, Anas N, Meyer K, Checchia PA, Lin R, Shanley TP, Bigham MT, Wheeler DS, Doughty LA, Tegtmeyer K, Poynter SE, Kaplan JM, Chima RS, Stalets E, Basu RK, Varisco BM, Barr FE: **Validation of a gene expression-based subclassification strategy for pediatric septic shock.** *Crit Care Med* 2011, **39**:2511-2517.
11. Wong HR, Wheeler DS, Tegtmeyer K, Poynter SE, Kaplan JM, Chima RS, Stalets E, Basu RK, Doughty LA: **Toward a clinically feasible gene expression-based subclassification strategy for septic shock: proof of concept.** *Crit Care Med* 2010, **38**:1955-1961.
12. Wong HR, Freishtat RJ, Monaco M, Odoms K, Shanley TP: **Leukocyte subset-derived genome-wide expression profiles in pediatric septic shock.** *Pediatr Crit Care Med* 2010, **11**:349-355.
13. Wong HR, Cvijanovich N, Lin R, Allen GL, Thomas NJ, Willson DF, Freishtat RJ, Anas N, Meyer K, Checchia PA, Monaco M, Odom K, Shanley TP: **Identification of pediatric septic shock subclasses based on genome-wide expression profiling.** *BMC Med* 2009, **7**:34.
14. Wong HR, Cvijanovich N, Allen GL, Lin R, Anas N, Meyer K, Freishtat RJ, Monaco M, Odoms K, Sakthivel B, Shanley TP: **Genomic expression profiling across the pediatric systemic inflammatory response syndrome, sepsis, and septic shock spectrum.** *Crit Care Med* 2009, **37**:1558-1566.
15. Wong HR, Cvijanovich N, Wheeler DS, Bigham MT, Monaco M, Odoms K, Macias WL, Williams MD: **Interleukin-8 as a stratification tool for interventional trials involving pediatric septic shock.** *Am J Resp Crit Care Med* 2008, **178**:276-282.
16. Cvijanovich N, Shanley TP, Lin R, Allen GL, Thomas NJ, Checchia P, Anas N, Freishtat RJ, Monaco M, Odoms K, Sakthivel B, Wong HR: **Validating the genomic signature of pediatric septic shock.** *Physiol Genomics* 2008, **34**:127-134.
17. Shanley TP, Cvijanovich N, Lin R, Allen GL, Thomas NJ, Doctor A, Kalyanaraman M, Tofil NM, Penfil S, Monaco M, Odoms K, Barnes M, Sakthivel B, Aronow BJ, Wong HR: **Genome-level longitudinal expression of signaling pathways and gene networks in pediatric septic shock.** *Mol Med* 2007, **13**:495-508.
18. Wong HR, Shanley TP, Sakthivel B, Cvijanovich N, Lin R, Allen GL, Thomas NJ, Doctor A, Kalyanaraman M, Tofil NM, Penfil S, Monaco M, Tagavilla MA, Odoms K, Dunsmore K, Barnes M, Aronow BJ: **Genome-level expression profiles in pediatric septic shock indicate a role for altered zinc homeostasis in poor outcome.** *Physiol Genomics* 2007, **30**:146-155.
19. Goldstein B, Giroir B, Randolph A: **International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics.** *Ped Crit Care Med* 2005, **6**:2-8.
20. Nowak JE, Wheeler DS, Harmon KK, Wong HR: **Admission chemokine (C-C motif) ligand 4 levels predict survival in pediatric septic shock.** *Pediatr Crit Care Med* 2010, **11**:213-216.
21. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP: **Exploration, normalization, and summaries of high density oligonucleotide array probe level data.** *Biostatistics* 2003, **4**:249-264.
22. Gene Expression Omnibus. [http://www.ncbi.nlm.nih.gov/geo/].
23. Eichler GS, Huang S, Ingber DE: **Gene Expression Dynamics Inspector (GEDi): for integrative analysis of expression profiles.** *Bioinformatics* 2003, **19**:2321-2322.
24. Guo Y, Eichler GS, Feng Y, Ingber DE, Huang S: **Towards a holistic, yet gene-centered analysis of gene expression profiles: a case study of human lung cancers.** *J Biomed Biotech* 2006, **2006**:69141.
25. Muller R, Mockel M: **Logistic regression and CART in the analysis of biomarker studies.** *Clin Chim Acta* 2008, **394**:1-6.
26. VassarStats Website for Statistical Computation. [http://faculty.vassar.edu/lowry/VassarStats.html].
27. Wojno ED, Hunter CA: **New directions in the basic and translational biology of interleukin-27.** *Trends Immunol* 2012, **33**:91-97.
28. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, Hibbert L, Churakova T, Travis M, Vaisberg E, Blumenschein WM, Mattson JD, Wagner JL, To W, Zurawski S, McClanahan TK, Gorman DM, Bazan JF, de Waal Malefyt R, Rennick D, Kastelein RA: **IL-27, a heterodimeric cytokine composed of EB13 and p28 protein, induces proliferation of naive CD4 (+) T cells.** *Immunity* 2002, **16**:779-790.
29. Villarino AV, Larkin J, Saris CJ, Caton AJ, Lucas S, Wong T, de Sauvage FJ, Hunter CA: **Positive and negative regulation of the IL-27 receptor during lymphoid cell activation.** *J Immunol* 2005, **174**:7684-7691.
30. Wirtz S, Tubbe I, Galle PR, Schild HJ, Birkenbach M, Blumberg RS, Neurath MF: **Protection from lethal septic peritonitis by neutralizing the biological function of interleukin 27.** *J Exp Med* 2006, **203**:1875-1881.
31. Gibot S, Benet MC, Noel R, Massin F, Guy J, Craviosy A, Barraud D, De Carvalho Bittencourt M, Quenot JP, Bollaert PE, Faure G, Charles PE: **Combination biomarkers to diagnose sepsis in the critically ill patients.** *Am J Respir Crit Care Med* 2012, **186**:65-71.

doi:10.1186/cc11847

Cite this article as: Wong et al.: Interleukin-27 is a novel candidate diagnostic biomarker for bacterial infection in critically ill children. *Critical Care* 2012 **16**:R213.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

